Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DN1508052 |
| Synonyms | |
| Therapy Description |
DN1508052 acts as an agonist of TLR8, potentially resulting in activation of NFkappaB signaling and increased anti-tumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DN1508052 | DN 1508052|DN1508052-01|DN A1|DN-A1|DN-1508052 | TLR8 Agonist 10 | DN1508052 acts as an agonist of TLR8, potentially resulting in activation of NFkappaB signaling and increased anti-tumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03934359 | Phase I | DN1508052 | A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors | Completed | USA | 0 |